Perceptual Modifying Compounds and Their Potential Therapeutic Applications in Neuropsychiatric Disorders.
ACS medicinal chemistry letters – January 11, 2024
Source: PubMed
Summary
Breakthrough research reveals how psychedelic compounds reshape brain circuits to combat depression, anxiety, and addiction. These substances promote neural growth and enhance brain plasticity by activating key cellular pathways. Working through the brain's command center, they strengthen connections in areas controlling mood and fear, offering rapid relief where traditional treatments often fall short.
Abstract
Psychedelic compounds, including ketamine and LSD, have gained renewed interest as potential treatments for neuropsychiatric disorders. These compounds act as psychoplastogens, promoting neuronal growth by activating AMPA receptors, TrkB, and mTOR. The prefrontal cortex plays a crucial role in their therapeutic effects through top-down control over brain regions involved in motivation, fear, and reward. Some of these compounds exhibit antidepressant effects by enhancing synaptic plasticity and neurogenesis while also demonstrating anxiolytic properties through the modulation of fear circuits. Additionally, they show promise as anti-addictive agents by disrupting addictive patterns and promoting neuroplasticity. The exploration of how psychedelic substances can be therapeutically beneficial reveals new opportunities for addressing conditions like major depressive disorder, anxiety, and addiction.